My Portfolio
+
LINK YOUR PORTFOLIO

Denali Therapeutics Inc DNLI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 06/02/26 EDT
19.66quote price arrow up+0.31 (+1.60%)
Volume
994,627
52 week range
12.58 - 23.77
Loading...
  • Open19.34
  • Day High19.69
  • Day Low19.19
  • Prev Close19.66
  • 52 Week High23.77
  • 52 Week High Date02/03/26
  • 52 Week Low12.58
  • 52 Week Low Date09/22/25

Latest On Denali Therapeutics Inc

Key Stats

  • Market Cap3.12B
  • Shares Out158.71M
  • 10 Day Average Volume1.89M
  • Dividend-
  • Dividend Yield-
  • Beta1.01

Latest On Denali Therapeutics Inc

KEY STATS

  • Open19.34
  • Day High19.69
  • Day Low19.19
  • Prev Close19.66
  • 52 Week High23.77
  • 52 Week High Date02/03/26
  • 52 Week Low12.58
  • 52 Week Low Date09/22/25
  • Market Cap3.12B
  • Shares Out158.71M
  • 10 Day Average Volume1.89M
  • Dividend-
  • Dividend Yield-
  • Beta1.01

RATIOS/PROFITABILITY

  • EPS (TTM)-2.88
  • P/E (TTM)-6.82
  • Fwd P/E (NTM)-7.45
  • EBITDA (TTM)-531.758M
  • ROE (TTM)-49.59%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-33,121.86%
  • Debt To Equity (MRQ)0.60%

EVENTS

  • Earnings Date08/10/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and...
Julian Baker
Independent Chairman of the Board
Ryan Watts Ph.D.
President, Chief Executive Officer, Director
Alexander Schuth M.D.
Chief Operating and Financial Officer, Secretary
Address
161 Oyster Point Blvd.
South San Francisco, CA
94080
United States